What question did this study set out to answer?

To explore the pharmacokinetic and pharmacodynamic evidence of ceftazidime-avibactam for treating CNS infections in pediatric patients.

April 16, 2026Open Access

Ceftazidime-avibactam-based regimens for the treatment of central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae in a pediatric patient

Key Points

To explore the pharmacokinetic and pharmacodynamic evidence of ceftazidime-avibactam for treating CNS infections in pediatric patients.
Assessment of ceftazidime-avibactam combined with intraventricular polymyxin B
Evaluation of effectiveness against carbapenem-resistant Klebsiella pneumoniae
Focus on pediatric population with CNS infections
Ceftazidime-avibactam shows potential effectiveness for treating pediatric meningitis caused by CRKP.
Combination therapy with polymyxin B may enhance therapeutic outcomes.
Emphasizes the need for further studies on dosing and long-term safety.

Abstract

This report adds to the limited pharmacokinetic/pharmacodynamic (PK/PD) evidence for ceftazidime-avibactam in pediatric CNS infections. It also supports the potential role of ceftazidime-avibactam combined with intraventricular polymyxin B as a therapeutic option for CRKP meningitis in children. Further studies are needed to optimize dosing strategies and evaluate long-term safety in the pediatric population.

Ceftazidime-avibactam-based regimens for the treatment of central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae in a pediatric patient

Key Points

Abstract

Cite This Study